Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5227332 | 0.98 | NPSR1 (0.33) | MAPTALDH1A1L3MBTL1NPSR1DGAT1 | |
| SCHEMBL28067161 | 0.90 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL15461486 | 0.80 | MAPT (0.34) | MAPTALDH1A1L3MBTL1NPSR1DGAT1 | |
| Hydrochloric Acid SCHEMBL25233263 | 0.79 | MAPT (0.49) | MAPTALDH1A1L3MBTL1NPSR1 | |
| SCHEMBL4734782 | 0.78 | MAPT (0.47) | MAPTALDH1A1L3MBTL1NPSR1 | |
| SCHEMBL15461474 | 0.78 | NPSR1 (0.32) | MAPTALDH1A1L3MBTL1NPSR1DGAT1 | |
| SCHEMBL1782571 | 0.76 | MME (0.33) | MAPTALDH1A1L3MBTL1EPHX1 | |
| SCHEMBL5389558 | 0.75 | MME (0.36) | MAPTALDH1A1L3MBTL1GAA | |
| SCHEMBL3525418 | 0.75 | CA12 (0.42) | MAPTALDH1A1L3MBTL1NPSR1DGAT1 | |
| Water SCHEMBL6244439 | 0.75 | MME (0.32) | MAPTALDH1A1L3MBTL1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167493-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2007-07-19 | — | — | US | disclosed |
| US-7223777-B2 | Compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. (IN) | 2007-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167493-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | AGER, GLA, F12 | MAPT 4043/4885ALDH1A1 226/4885L3MBTL1 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.